Sign in Subscribe

Artiva Biotherapeutics Stock Soars: Wedbush Raises Price Target to $23 on Breakthrough RA Treatment

Wedbush upgrades Artiva Biotherapeutics price target to $23 citing FDA Fast Track for AlloNK therapy targeting refractory rheumatoid arthritis with potential 2026 pivotal trial.

Artiva Biotherapeutics Stock Soars: Wedbush Raises Price Target to $23 on Breakthrough RA Treatment
Photo by roger vaughan on Unsplash
Already have an account? Sign in.